PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME®/GENERIC DRUG NAME: TEFLARO OR ZINFORO PROTOCOL NO.: D3720C00009 (C2661002) PROTOCOL TITLE: Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline in Neonates and Young Infants with Late-Onset Sepsis Study Centers: The study was conducted at 25 sites in the United States (US), Hungary, Italy, Spain, and Lithuania; 3 sites in Hungary and 1 in the US enrolled patients, 1 site in the US screened 1 patient but did not enroll any patients. The additional 20 sites were initiated but did not enroll any patients. Study Initiation Date and Primary Completion or Final Completion Dates: Study Initiation Date =04 Aug 2015; Primary Completion Date =30 Dec 2017 Phase of Development: Phase 2 Study Objectives: Primary Objective: To evaluate the safety and tolerability of ceftaroline for the treatment of late-onset sepsis (LOS) in neonates and young infants aged 7 to <60 days. Secondary Objectives: To evaluate the pharmacokinetic (PK) profile of ceftaroline in neonates and young infants aged 7 to <60 days with LOS. To evaluate the efficacy of ceftaroline for the treatment of LOS in neonates and young infants aged 7 to <60 days. TThhiiss wwaass aa mmuullttiicceennttrree,, mmuullttiinnaattiioonnaall,, ooppeenn-llaabbeell,, ssiinnggllee ttrreeaattmmeenntt aarrmm ssttuuddyy ooff iinnttrraavveennoouuss (((IIIVVV))) ccceeeffftttaaarrrooollliiinnneee fffooosssaaammmiiilll aaannnddd aaammmpppiiiccciiilllllliiinnn,,, pppllluuusss aaannn oooppptttiiiooonnnaaalll aaammmiiinnnoooggglllyyycccooosssiiidddeee ooofff ccchhhoooiiiccceee,,, iiinnn hhoossppiittaalliizzeedd nneeoonnaatteess aanndd yyoouunngg iinnffaannttss aaggeedd 77 ttoo <<6600 ddaayyss wwiitthh llaattee -oonnsseett sseeppssiiss ((LLOOSS)).. Study patients received ceftarrrooollliiinnneee fffooosssaaammmiiilll aaattt aaa dddooossseee ooofff 666 mmmggg///kkkggg IIIVVV ooovvveeerrr 666000 (((±±±111000))) mmmiiinnnuuuttteeesss qqq888hhh (((±±±111 hhhooouuurrr)))... (((PPPaaatttiiieeennntttsss eeennnrrrooolllllleeeddd ppprrriiiooorrr tttooo aaammmeeennndddmmmeeennnttt 222 [[[PPPrrroootttooocccooolll eeedddiiitttiiiooonnn 333]]] rrreeeccceeeiiivvveeeddd cceeffttaarroolliinnee ffoossaammiill aatt aa ddoossee ooff 44 mmgg//kkgg oovveerr 6600 [[±±1100]] mmiinnuutteess qq88hh [[±±11 hhoouurr]]..)) IIff tthhee presence of an organismmm ttthhhaaattt rrreeeqqquuuiiirrreeeddd tttrrreeeaaatttmmmeeennnttt wwwiiittthhh aaammmpppiiiccciiilllllliiinnn cccooouuulllddd nnnooottt bbbeee eeexxxcccllluuudddeeeddd,,, ttthhheeennn ttthhheee uuussseee ooofff IIIVVV aaammmpppiiiccciiilllllliiinnn fffooorrr ttthhheee fffiiirrrsssttt 444888 hhhooouuurrrsss wwwaaasss mmmaaannndddaaatttooorrryyy... TTThhheee uuussseee ooofff aaannn aaammmiiinnnoooggglllyyycccooosssiiidddeee wwwaaasss cccooonnnsssiiidddeeerrreeeddd oooppptttiiiooonnnaaalll fffrrrooommm BBBaaassseeellliiinnneee ttthhhrrrooouuuggghhh ttthhheee eeennntttiiirrreee ssstttuuudddyyy... GGGeeennntttaaammmiiiccciiinnn wwwaaasss ttthhheee preferred aminoglycoside. PPaattiieennttss ppaarrttiicciippaatteedd iinn tthhee ssttuuddyy ffoorr uupp ttoo 4499 ddaayyss.. TThhee ttoottaall dduurraattiioonn ooff ssttuuddyy tthheerraappyy wwaass 48 hours (minimum) to 14 dddaaayyysss (((mmmaaaxxxiiimmmuuummm)))... HHHooossspppiiitttaaallliiizzzaaatttiiiooonnn wwwaaasss rrreeeqqquuuiiirrreeeddd ddduuurrriiinnnggg IIIVVV ssstttuuudddyyy tthheerraappyy.. BBaasseelliinnee aasssseessssmmeennttss ffoorr ssttuuddyy eelliiggiibbiilliittyy oocccurred within 36 hhoouurrss bbeeffoorree tthhee ffiirrsstt ddoossee ooff ssttuuddyy tthheerraappyy.. TThhee SSaaffeettyy FFoollllooww-uupp ((SSFFUU)) aasssseessssmmeennttss ooccccuurrrreedd 2211 to 35 days after tthhee llaasstt ddoossee ooff ssttuuddyy tthheerraappyy.. SSaaffeettyy aasssseessssmmeennttss wweerree ddoonnee tthhrroouugghhoouutt tthhee ssttuuddyy.. BBeettwweeeenn DDaayyss 22 aanndd 1144,, 22 blood samples weeerrreee cccooolllllleeecccttteeeddd fffooorrr PPPKKK aaannnaaalllyyysssiiisss... TTThhheee eeeffffffiiicccaaacccyyy ooofff ccceeeffftttaaarrrooollliiinnneee wwwaaasss eeevvvaaallluuuaaattteeeddd bbbaaassseeeddd ooonnn ttthhheee cccllliiinnniiicccaaalll ooouuutttcccooommmeee (((cccllliiinnniiicccaaalll cccuuurrreee,,, cccllliiinnniiicccaaalll fffaaaiiillluuurrreee,,, ooorrr iiinnnttteeerrrmmmeeedddiiiaaattteee))) aaattt eeennnddd ooofff ttthhheeerrraaapppyyy (((EEEOOOTTT))) and test-of-ccuurree ((TTOOCC)) aasssseessssmmeennttss.. TThhee ssttuuddyy ttiimmeelliinnee iiss ssuummmmaarriizzeedd iinn Figure 1. Figure 1. Study Diagram Abbreviations: EOT = End-of-TTThhheeerrraaapppyyy,,, IIICCCDDD === iiinnnfffooorrrmmmeeeddd cccooonnnssseeennnttt dddooocccuuummmeeennnttt,,, IIIVVV === iiinnntttrrraaavvveeennnooouuusss,,, IXRS = IInntteerraaccttiivvee RReessppoonnssee SSyysstteemm,, PPCCRR == ppoollyymmeerraassee cchhaaiinn rreeaaccttiioonn,, PPKK = pphhaarrmmaaccookkiinneettiicc,, SFU = Safety Follow-uupp,, TTOOCC == TTeesstt-of-Cure ***IIIVVV aaammmpppiiiccciiilllllliiinnn aaannnddd aaannn oooppptttiiiooonnnaaalll aaammmiiinnnoooggglllyyycccooosssiiidddeee wwweeerrreee gggiiivvveeennn aaasss pppeeerrr ssstttaaannndddaaarrrddd ooofff cccaaarrreee... IIIfff ttthhheee ppprrreeessseeennnccceee ooofff aaannn organism that requireddd tttrrreeeaaatttmmmeeennnttt wwwiiittthhh aaammmpppiiiccciiilllllliiinnn cccooouuulllddd nnnooottt bbbeee eeexxxcccllluuudddeeeddd,,, ttthhheeennn ttthhheee uuussseee ooofff IIIVVV aaammmpppiiiccciiilllllliiinnn fffooorrr ttthhheee fffiiirrrsssttt 444888 hhhooouuurrrsss ooofff tttrrreeeaaatttmmmeeennnttt wwwaaasss mmmaaannndddaaatttooorrryyy... IIIfff ttthhheee rrreeesssuuullltttsss ooofff aaaddddddiiitttiiiooonnnaaalll mmmiiicccrrrooobbbiiiooolllooogggyyy,,, PPPCCCRRR,,, ooorrr ooottthhheeerrr iinnvveessttiiggaattiioonnss iinnddiiccaatteedd tthhaatt aammppiicciilllliinn dduurriinngg tthhee ffiirrsstt 4488 hhoouurrss ooff ttrreeaattmmeenntt wwaass nnoott rreeqquuiirreedd,, tthheenn iittss uussee wwaass aatt tthhee ddiissccrreettiioonn ooff tthhee IInnvveessttiiggaattoorr.. procedures. Table 1. Schedule of Activities Baselinea * Study Day 1 started at the onset of study therapy and ended 24 hours later. Subsequent Study Days followed the same pattern. Abbreviations: AEs = adverse events; CBC = complete blood count; CRP = C-reactive protein; CSF = cerebrospinal fluid; CT = computed tomography; CXR = chest radiograph; EOT = End-of-Therapy; MRI = magnetic resonance imaging; PK = pharmacokinetic; SAEs = serious adverse events; SFU = Safety Follow-up; TOC = Test-of-Cure. a. Baseline assessments conducted within 36 hours before the first dose of study therapy. b. EOT assessments conducted within 24 hours after the end of the last infusion. Study therapy may or may not have been given on the same calendar day as EOT assessments; administration was as for days 4-14. c. TOC assessments conducted 8 to 15 days after the last dose of study therapy. d. SFU assessments conducted, preferably in person, 21 to 35 days after the last dose of study therapy. The SFU may have been conducted via telephone for any patient who did not experience clinical relapse, did not have ongoing AEs or SAEs at TOC, or did not develop AEs or SAEs since TOC. If symptoms of were performed. e. RRReeefffeeerrr tttooo ttthhheee iiinnncccllluuusssiiiooonnn cccrrriiittteeerrriiiaaa fffooorrr ttthhheee rrreeecccooommmmmmeeennndddeeeddd dddeeefffiiinnniiitttiiiooonnnsss ooofff cccllliiinnniiicccaaalll aaannnddd lllaaabbbooorrraaatttooorrryyy iiinnncccllluuusssiiiooonnn cccrrriiittteeerrriiiaaa... f. FFFooorrr pppaaatttiiieeennntttsss wwwhhhooo wwweeerrreee bbbeeeiiinnnggg bbbrrreeeaaassstttfffeeeddd,,, aaallllll mmmeeedddiiicccaaatttiiiooonnnsss tttaaakkkeeennn bbbyyy ttthhheee lllaaaccctttaaatttiiinnnggg mmmooottthhheeerrr fffooorrr 333 dddaaayyysss bbbeeefffooorrreee ttthhheee ffiirrsstt ddoossee ooff ssttuuddyy tthheerraappyy tthhrroouugghh SSFFUU wweerree rreeccoorrddeedd.. g. Post-bbaasseelliinnee,, hhiigghheesstt aanndd lloowweesstt ppoosstt ddoossee tteemmppeerraattuurree mmeeaassuurreemmeennttss wweerree rreeccoorrddeedd.. h. Obtained attt bbbaaassseeellliiinnneee,,, rrreeesssuuullltttsss ooofff CCCXXXRRR,,, CCCTTT ssscccaaannn,,, ooorrr ooottthhheeerrr iiimmmaaagggiiinnnggg ttteeessstttsss (((eeeggg,,, eeeccchhhooocccaaarrrdddiiiooogggrrraaammm,,, CCCTTT,,, MMMRRRIII,,, sssooonnnooogggrrraaappphhhyyy))) iiifff pppeeerrrfffooorrrmmmeeeddd aaasss pppaaarrrttt ooofff ttthhheee pppaaatttiiieeennnttt’’’sss rrreeeggguuulllaaarrr mmmeeedddiiicccaaalll cccaaarrreee wwwiiittthhhiiinnn 777222 hhhooouuurrrsss bbbeeefffooorrreee ttthhheee fffiiirrrsssttt dddooossseee of study therapy. i. RReeffeerr ttoo tthhee iinncclluussiioonn ccrriitteerriiaa ffoorr aa lliisstt ooff tteessttss,, rreeccoommmmeennddeedd ttoo rreeppeeaatt aatt lleeaasstt eevveerryy 77 ddaayyss.. IIff iimmmmaattuurree nnneeeuuutttrrroooppphhhiiilllsss wwweeerrreee aaavvvaaaiiilllaaabbbllleee,,, III///TTT nnneeeuuutttrrroooppphhhiiilll rrraaatttiiiooo cccaaalllcccuuulllaaattteeeddd uuusssiiinnnggg ttthhheee fffooorrrmmmuuulllaaa::: j. If clinically indicated. k. FFoorr ppaattiieennttss wwhhoo hhaadd bbeeeenn hhoossppiittaalliizzeedd ffoorr ≥≥88 hhoouurrss,, uurriinnee oouuttppuutt ccaallccuullaatteedd oovveerr tthhee llaasstt 88 hhoouurr ppeerriioodd.. l. PPPaaatttiiieeennntttsss wwweeerrreee rrraaannndddooommmlllyyy aaassssssiiigggnnneeeddd (((111:::111))) tttooo 111 ooofff ttthhheee fffooollllllooowwwiiinnnggg PPPKKK sssccchhheeeddduuullleeesss cccooolllllleeecccttteeeddd aaafffttteeerrr aaannnyyy dddooossseee bbbeeetttwwweeeeeennn the end of the 444ttthhh iiinnnfffuuusssiiiooonnn ooofff ccceeeffftttaaarrrooollliiinnneee fffooosssaaammmiiilll aaannnddd bbbeeefffooorrreee EEEOOOTTT ooorrr SSStttuuudddyyy DDDaaayyy 111444 (((wwwhhhiiiccchhheeevvveeerrr wwwaaasss eeeaaarrrllliiieeerrr)))::: PPPKKK SSSccchhheeeddduuullleee 111::: aaattt ttthhheee eeennnddd ooofff ttthhheee ccceeeffftttaaarrrooollliiinnneee fffooosssaaammmiiilll iiinnnfffuuusssiiiooonnn (((±±±555 mmmiiinnnuuuttteeesss))) aaannnddd 333 tttooo 444 hhhooouuurrrsss aaafffttteeerrr ttthhheee eeennnddd ooofff the infusion. PPKK SScchheedduullee 22:: 1155 mmiinnuutteess ttoo 22 hhoouurrss aafftteerr tthhee eenndd ooff tthhee cceeffttaarroolliinnee ffoossaammiill iinnffuussiioonn aanndd 55 ttoo 77 hhoouurrss aafftteerr tthhee eenndd ooff tthhee iinnffuussiioonn ((bbeeffoorree tthhee ssttaarrtt ooff tthhee nneexxtt iinnffuussiioonn)).. m. PPPKKK bbblllooooooddd sssaaammmpppllleeesss wwweeerrreee NNNOOOTTT tttooo bbbeee dddrrraaawwwnnn iiifff ttthhheee pppaaatttiiieeennnttt hhhaaaddd rrreeeccceeeiiivvveeeddd aaa bbblllooooooddd ooorrr bbblllooooooddd cccooommmpppooonnneeennnttt transfusion within the past 2444 hhhooouuurrrsss... FFFooorrr pppaaatttiiieeennntttsss wwwhhhooo wwweeerrreee aaattt rrriiissskkk fffrrrooommm aaaddddddiiitttiiiooonnnaaalll bbblllooooooddd lllooossssss,,, ttthhheee ccoolllleeccttiioonn ooff PPKK ssaammpplleess rreeqquuiirreedd aasssseessssmmeenntt bbyy tthhee IInnvveessttiiggaattoorr.. n. MMMaaatttccchhhiiinnnggg bbblllooooooddd sssaaammmpppllleee tttooo bbbeee cccooolllllleeecccttteeeddd ooonnnlllyyy iiifff 222 PPPKKK bbblllooooooddd sssaaammmpppllleeesss hhhaaaddd nnnooottt aaalllrrreeeaaadddyyy bbbeeeeeennn cccooolllllleeecccttteeeddd... TTThhheee matching blood saaammmpppllleee rrreeeppplllaaaccceeeddd 111 ooofff ttthhheee PPPKKK sssaaammmpppllleeesss sssooo ttthhhaaattt ttthhheee tttoootttaaalll nnnuuummmbbbeeerrr ooofff PPPKKK sssaaammmpppllleeesss dddiiiddd nnnooottt exceed 2. NNuummbbeerr ooff SSuubbjjeeccttss ((PPllaannnneedd aanndd AAnnaallyyzzeedd)):: TThhee ssttuuddyy wwaass ttoo bbee ccoonndduucctteedd iinn aapppprrooxxiimmaatteellyy 3300 cceenntteerrss wwoorrllddwwiiddee.. AAtt lleeaasstt 2244 patients wwiitthh LLOOSS wweerree ttoo bbee eennrroolllleedd and treated within 3 age cohorts of 8 ppaattiieennttss eeaacchh:: yyoouunngg infants aged >28 ddaayyss ttoo <<6600 days (cohort 1), term neonates aged 7 to 28 ddaayyss ((ccoohhoorrtt 22)),, and preterm neonates aged 7 to 28 days (cohort 3). EElleevveenn ((1111)) ppaattiieennttss wweerree eennrroolllleedd iinn tthhee ssttuuddyy aatt 44 cceenntteerrss,, 33 iinn HHuunnggaarryy aanndd 11 iinn tthhee UUSS.. FFFooouuurrr pppaaatttiiieeennntttsss wwweeerrreee eeennnrrrooolllllleeeddd iiinnn cccooohhhooorrrttt 111;;; 555 pppaaatttiiieeennntttsss wwweeerrreee eeennnrrrooolllllleeeddd iiinnn cccooohhhooorrrttt 222;;; aaannnddd 222 pppaaatttiiieeennntttsss were enrolled in cohort 3. IIInnn AAAuuuggguuusssttt 222000111777 PPPfffiiizzzeeerrr sssuuubbbmmmiiitttttteeeddd aaa mmmooodddiiifffiiicccaaatttiiiooonnn tttooo ttthhheee PPPaaaeeedddiiiaaatttrrriiiccc IIInnnvvveeessstttiiigggaaatttiiiooonnn PPPlllaaannn (((PPPIIIPPP))) tttooo ttthhheee EEEuuurrrooopppeeeaaannn MMMeeedddiiiccciiinnneeesss AAAgggeeennncccyyy (((EEEMMMAAA))) PPPaaaeeedddiiiaaatttrrriiiccc CCCooommmmmmiiitttttteeeeee (((PPPDDDCCCOOO))),,, rrreeeqqquuueeessstttiiinnnggg ccclllooosssuuurrreee ooofff ttthhheee CCC222666666111000000222 ssstttuuudddyyy bbbaaassseeeddd ooonnn PPPfffiiizzzeeerrr’’’sss ooopppiiinnniiiooonnn ttthhhaaattt ttthhheeerrreee wwwaaasss sssuuuffffffiiiccciiieeennnttt dddaaatttaaa aaavvvaaaiiilllaaabbbllleee tttooo ppprrrooovvviiidddeee ccceeeffftttaaarrrooollliiinnneee fffooosssaaammmiiilll dddooosssiiinnnggg rrreeecccooommmmmmeeennndddaaatttiiiooonnnsss fffooorrr nnneeeooonnnaaattteeesss... TTThhheee sssaaammmeee rrreeeqqquuueeessst was ssuubbmmiitttteedd ttoo tthhee UUSS FFDDAA bbyy AAlllleerrggaann iinn NNoovveemmbbeerr 22001177.. FFFiiinnnaaalll ooopppiiinnniiiooonnnsss wwweeerrreee rrreeeccceeeiiivvveeeddd fffrrrooommm PPPDDDCCCOOO (((222222 DDDeeeccc 222000111777))),,, EEEMMMAAA (((222666 JJJaaannn 222000111888))),,, aaannnddd ttthhheee FFFDDDAAA (((222888 JJJaaannn 222000111888))),,, iiinnndddiiicccaaatttiiinnnggg ttthhheee AAAgggeeennnccciiieeesss’’’ aaagggrrreeeeeemmmeeennnttt wwwiiittthhh eeeaaarrrlllyyy ccclllooosssuuurrreee ooofff ttthhheee ssstttuuudddyyy wwwiiittthhh ttthhheee current enrollment ooofff 111111 pppaaatttiiieeennntttsss... WWWiiittthhh ttthhhiiisss dddeeeccciiisssiiiooonnn,,, ttthhheee ssstttuuudddyyy cccooommmpppllleeetttiiiooonnn dddaaattteee iiisss cccooonnnsssiiidddeeerrreeeddd 30 Dec 2017. DDiiaaggnnoossiiss aanndd MMaaiinn CCrriitteerriiaa ffoorr IInncclluussiioonn aanndd EExxcclluussiioonn:: EEEllliiigggiiibbbllleee pppaaatttiiieeennntttsss wwweeerrreee eeexxxpppeeecccttteeeddd tttooo mmmeeeeeettt ttthhheee fffooollllllooowwwiiinnnggg aaannnddd aaallllll ooottthhheeerrr qqquuuaaallliiifffyyyiiinnnggg cccrrriiittteeerrriiiaaa::: representative(s).  Male or female, gestational age 34 weeks, and chronological age 7 to <60 days at the time of screening.  Diagnosis of sepsis within 36 hours before enrollment, defined as the presence of at least 2 clinical criteria and at least 1 laboratory criterion in the presence of or as a result of suspected or proven bacterial infection that required IV antibiotic therapy  Patients must have met at least 2 of the following clinical criteria: Hypothermia (<36° C) OR fever (>38.5° C); Bradycardia OR tachycardia OR rhythm instability; urine output 0.5 to 1 mL/kg/h OR hypotension OR mottled skin OR impaired peripheral perfusion; Petechial rash OR sclerema neonatorum; new onset or worsening of apnoea episodes OR tachypnoea episodes OR increased oxygen requirements OR requirement for ventilation support; Feeding intolerance OR poor sucking OR abdominal distension; irritability; lethargy; hypotonia.  Patients must have met at least 1 of the following laboratory criteria: white blood cell count 4.0 × 109/L OR 20.0 × 109/L; immature to total neutrophil ratio >0.2; platelet count 100 × 109/L; C-reactive protein (CRP) >15 mg/L OR procalcitonin 2 ng/mL; hyperglycaemia OR hypoglycaemia; metabolic acidosis. Patients with any of the following conditions were excluded from the study:  Documented history of any hypersensitivity or allergic reaction to any β-lactam antibiotic or aminoglycoside  At study entry, had confirmed infection with a pathogen known to be resistant to the combination of ceftaroline fosamil, ampicillin, and the optional aminoglycoside of choice OR confirmed viral, fungal, or parasitic pathogen as the sole cause of infection  Refractory septic shock within 24 hours before enrolment that did not resolve after 60 minutes of vasopressor therapy  Moderate or severe renal impairment defined as serum creatinine 2 times the upper limit of normal (×ULN) for age OR urine output <0.5 mL/kg/h (measured over at least 8 hours) OR requirement for dialysis  Evidence of progressively fatal underlying disease, or life expectancy of 60 days;  Documented history of seizure  Requiring or currently taking antiretroviral therapy for human immunodeficiency virus (HIV) or a child from an HIV positive mother  Proven or suspected central nervous system (CNS) infection (eg, meningitis, brain ampicillin, plus an optional aminoglycoside of choice as empiric therapy for LOS. The total duration of study therapy was 48 hours (minimum) to 14 days (maximum). In this study, all patients received ceftaroline fosamil, either 4 mg/kg or 6 mg/kg IV over 60 (±10) minutes q8h (±1 hour). IV ampicillin and an optional aminoglycoside were given as per standard of care. If the presence of an organism that required treatment with ampicillin could not be excluded, then the use of IV ampicillin for the first 48 hours of treatment was mandatory. If the results of additional microbiology, PCR, or other investigations indicated that ampicillin during the first 48 hours of treatment was not required, then its use was at the discretion of the Investigator. Efficacy and Pharmacokinetic Research Endpoints: Primary: There was no primary efficacy endpoint. Secondary:  Percentage of participants with favorable clinical response  Percentage of participants with favorable microbiological response  Plasma concentration of ceftaroline fosamil  Plasma concentration of ceftaroline  Plasma concentration of ceftaroline M-1 Safety Evaluations: Adverse events were collected from signing the informed consent document (ICD) until the SFU visit. Laboratory testing, including blood and urine samples, were collected according to the Schedule of Activities (Table 1) at Baseline and EOT. Samples could also be collected at any time during the treatment period, and at TOC and SFU if clinically indicated. Vital signs assessments including weight, heart rate, blood pressure (systolic and diastolic), respiratory rate, and temperature were assessed at the specified time points outlined in the Schedule of Activities (Table 1). Highest and lowest daily temperatures were monitored; length was collected at Baseline only. Medical and surgical history including antepartum/peripartum period, prior and concomitant medications, length, weight, and physical examination findings (including LOS physical findings and presence of central venous catheter or other medical devices) were recorded at Baseline and, if applicable, during the study according to the Schedule of Activities (Table 1). Figure 2. OOuuttlliinnee ooff AAnnaallyyssiiss SSeettss Abbbreviations: ITT=Intent-to-TTrreeaatt;; LLOOSS==llaattee-oonnsseett sseeppssiiss;; MMiiccrrooIITTTT==MMiiccrroobbiioollooggiiccaall IITTTT;; MMIITTTT==MMooddiiffiieedd ITT; PK=Pharmacokinetic DDDeeessscccrrriiippptttiiivvveee ssstttaaatttiiissstttiiicccsss (((nnnuuummmbbbeeerrr,,, mmmeeeaaannn,,, ssstttaaannndddaaarrrddd dddeeevvviiiaaatttiiiooonnn [[[SSSDDD]]],,, mmmeeedddiiiaaannn,,, mmmiiinnniiimmmuuummm,,, aaannnddd mmmaaaxxxiiimmmuuummm))) aaarrreee ppprrrooovvviiidddeeeddd fffooorrr cccooonnntttiiinnnuuuooouuusss vvvaaarrriiiaaabbbllleeesss,,, aaannnddd fffrrreeeqqquuueeennncccyyy dddiiissstttrrriiibbbuuutttiiiooonnnsss (((cccooouuunnntttsss aaannnddd pppeeerrrccceeennntttaaagggeeesss))) aaarrreee ssshhhooowwwnnn fffooorrr cccaaattteeegggooorrriiicccaaalll vvvaaarrriiiaaabbbllleeesss... AAAllllll vvvaaarrriiiaaabbbllleeesss aaarrreee sssuuummmmmmaaarrriiizzzeeeddd ooovvveeerrrall and by age cohort. PPPaaatttiiieeennnttt dddiiissspppooosssiiitttiiiooonnn (((eeennnrrrooollllllmmmeeennnttt,,, dddiiissscccooonnntttiiinnnuuuaaatttiiiooonnnsss fffrrrooommm ttthhheee ssstttuuudddyyy))) ooovvveeerrraaallllll aaannnddd wwwiiittthhhiiinnn eeeaaaccchhh aaagggeee ccoohhoorrtt iiss pprroovviiddeedd bbaasseedd oonn tthhee Intent-to-Treat (ITT) AAnnaallyyssiiss SSeett.. RReeaassoonnss ffoorr eexxcclluussiioonn ffrroomm ssttuuddyy aannaallyyssiiss sseettss aarree ssuummmmaarriizzeedd ffoorr tthhe ITT Analysis Set. DDDeeemmmooogggrrraaappphhhiiicccsss (((aaagggeee,,, rrraaaccceee,,, gggeeennndddeeerrr))),,, mmmeeedddiiicccaaalll aaannnddd sssuuurrrgggiiicccaaalll hhhiiissstttooorrryyy iiinnncccllluuudddiiinnnggg aaannnttteeepppaaarrrtttuuummm/// pppeeerrriiipppaaarrrtttuuummm pppeeerrriiioooddd,,, mmmiiicccrrrooobbbiiiooolllooogggiiicccaaalll aaasssssseeessssssmmmeeennnttt ooofff bbblllooooooddd,,, CCCSSSFFF,,, uuurrriiinnneee,,, aaannnddd ooottthhheeerrr ssspppeeeccciiimmmeeennnsss ooorrr ttiissssuuee ssaammpplleess aarree ssuummmmaarriizzeedd ffoorr tthhee IITTTT,, Modified Intent-to-Treat (MITT)), and Microbiological Intent-to-TTrreeaatt ((Micro-ITT) Analysis Sets. EEffffiiccaaccyy rreessppoonnssee wwaass aannaallyyzzeedd uussiinngg tthhee IITTTT,, MMIITTTT, and Micro-IITTTT AAnnaallyyssiiss SSeettss.. PPPrrrooopppooorrrtttiiiooonnnsss ooofff pppaaatttiiieeennntttsss wwwiiittthhh aaa fffaaavvvooorrraaabbbllleee eeeffffffiiicccaaacccyyy rrreeessspppooonnnssseee aaarrreee dddiiisssppplllaaayyyeeeddd ooovvveeerrraaallllll aaannnddd wwwiiittthhhiiinnn eeeaaaccchhh aaagggeee cccooohhhooorrrttt... TTThhheee nnnuuummmbbbeeerrr aaannnddd pppeeerrrccceeennntttaaagggeee ooofff pppaaatttiiieeennntttsss ccclllaaassssssiiifffiiieeeddd aaasss aaa cccllliiinnniiicccaaalll cccuuurrreee aaattt EEEOOOTTT aanndd TTOOCC aarree ttaabbuullaatteedd iinn tthhee IITTTT,, MMIITTTT aanndd MMiiccrroo-ITT Analysis Sets. TTThhheee ppprrrooopppooorrrtttiiiooonnn ooofff pppaaatttiiieeennntttsss wwwiiittthhh aaa cccllliiinnniiicccaaalll cccuuurrreee wwwaaasss dddeeefffiiinnneeeddd uuusssiiinnnggg ttthhheee fffooollllllooowwwiiinnnggg fffooorrrmmmuuulllaaa::: The ppprrrooopppooorrrtttiiiooonnn ooofff pppaaatttiiieeennntttsss wwwiiittthhh cccllliiinnniiicccaaalll fffaaaiiillluuurrreee aaannnddd wwwiiittthhh iiinnndddeeettteeerrrmmmiiinnnaaattteee cccllliiinnniiicccaaalll rrreeessspppooonnnssseee wwwaaasss cccaaalllcccuuulllaaattteeeddd aaannnaaalllooogggooouuussslllyyy... FFFooorrr ttthhheee ppprrrooopppooorrrtttiiiooonnn ooofff pppaaatttiiieeennntttsss wwwiiittthhh cccllliiinnniiicccaaalll cccuuurrreee,,, cccllliiinnniiicccaaalll fffaaaiiillluuurrreee,,, aaannnddd iinnddeetteerrmmiinnaattee,, iinnddeetteerrmmiinnaattee oorr mmiissssiinngg aasssseessssmmeennttss wweerree iinncclluuddeedd iinn tthhee ddeennoommiinnaattoorr ffoorr ccaallccuullaattiioonn ooff tthhee pprrooppoorrttiioonnss ffoorr tthhee IITTTT,, MMIITTTT aanndd MMiiccrroo-IITTTT AAnnaallyyssiiss SSeettss.. MMMiiicccrrrooobbbiiiooolllooogggiiicccaaalll sssuuucccccceeessssss aaattt EEEOOOTTT aaannnddd TTTOOOCCC wwwaaasss eeevvvaaallluuuaaattteeeddd... AAA sssuuummmmmmaaarrryyy ooofff ttthhheee mmmiiicccrrrooobbbiiiooolllooogggiiicccaaalll oouuttccoommee bbyy ppaattiieenntt aanndd bbyy ppaatthhooggeenn iiss pprreesseenntteedd iinn tthhee MMIITTTT aanndd MMiiccrro-IITTTT AAnnaallyyssiiss SSeettss.. RESULTS PPaattiieenntt DDiissppoossiittiioonn aanndd DDeemmooggrraapphhyy:: TThhee ssuummmmaarryy ooff ppaattiieenntt ddiissppoossiittiioonn iiss pprreesseenntteedd iinn Table 2.. EElleevveenn ((1111)) ppaattiieennttss wweerree enrolled in ttthhheee ssstttuuudddyyy aaannnddd rrreeeccceeeiiivvveeeddd ssstttuuudddyyy tttrrreeeaaatttmmmeeennnttt::: 444 (((333666...444%%%))) pppaaatttiiieeennntttsss wwweeerrreee iiinnn CCCooohhhooorrrttt 111 (((yyyooouuunnnggg iiinnnfffaaannntttsss))),,, 555 (((444555...555%%%))) iiinnn CCCooohhhooorrrttt 222 (((ttteeerrrmmm nnneeeooonnnaaattteeesss))),,, aaannnddd 222 (((111888...222%%%))) iiinnn CCCooohhhooorrrttt 333 (((ppprrreeettteeerrrmmm nnneeeooonnnaaattteeesss)))... AAAllllll eeennnrrrooolllllleeeddd pppaaatttiiieeennntttsss cccooommmpppllleeettteeeddd ttthhheee ssstttuuudddyyy... SSSeeevvveeennn (((777;;; 666333...666%%%))) pppaaatttiiieeennntttsss cccooommmpppllleeeted treatment (Table 2). The 4 (((333666...444%%%))) pppaaatttiiieeennntttsss wwwhhhooo wwweeerrreee dddiiissscccooonnntttiiinnnuuueeeddd fffrrrooommm ssstttuuudddyyy tttrrreeeaaatttmmmeeennnttt wweerree aallll eennrroolllleedd aatt 11 ssiittee iinn tthhee UUSS.. TThheessee 44 ppaattiieennttss hhaadd iimmpprroovveedd ttoo tthhee eexxtteenntt tthhaatt dddiiisssccchhhaaarrrgggeee fffrrrooommm ttthhheee hhhooossspppiiitttaaalll wwwaaasss dddeeesssiiirrreeeddd... AAAsss ttthhheee ppprrroootttooocccooolll ppprrrooohhhiiibbbiiittteeeddd ssstttuuudddyyy tttrrreeeaaatttmmmeeennnttt fffrrrooommm bbbeeeiiinnnggg aaadddmmmiiinnniiisssttteeerrreeeddd iiinnn aaannn ooouuutttpppaaatttiiieeennnttt ssseeettttttiiinnnggg,,, ttthhheee IIInnnvvveeessstttiiigggaaatttooorrr dddiiissscccooonnntttiiinnnuuueeeddd ccceeeffftttaaarrrooollliiinnneee fffooosssaaammmiiilll IIVV aanndd sswwiittcchheedd tthhee ppaattiieennttss ttoo ootthheerr ssttaannddaarrdd ooff ccaarree oorraall//IIVV aannttiibbaacctteerriiaall tthheerraappyy ffoorr ccoonnttiinnuueedd ttrreeaattmmeenntt ooff LLOOSS uuppoonn hhoossppiittaall ddiisscchhaarrggee.. AAAcccrrrooossssss aaallllll pppaaatttiiieeennntttsss,,, ttthhheee mmmeeeaaannn aaagggeee wwwaaasss 333000...333 ±±±111444...888 dddaaayyysss (((mmmeeedddiiiaaannn 222444...000,,, rrraaannngggeee 111222-53 days). GGGeeennndddeeerrr aaacccrrrooossssss aaallllll cccooohhhooorrrtttsss wwwaaasss nnneeeaaarrrlllyyy eeevvveeennnlllyyy dddiiivvviiidddeeeddd,,, wwwiiittthhh 555 (((444555...555%%%))) fffeeemmmaaallleeesss aaannnddd 666 (((555444...555%%%))) (1 [9.1%] Hispanic or Latino), and 1 (9.1%) patient was Asian (Table 3). Efficacy and Pharmacokinetic Research Results: Analysis Sets: Table Patients Patients Patients Patients Patients The One During the site close-out visit at site 9004, after database lock, a new screen failure was discovered. No data Set.Cohort CRF Intent-to-Treat; Percentage of Participants with Favorable Clinical Response: Clinical response at EOT and TOC for the MITT Analysis Set is presented in Table 5. At both EOT and TOC, all patients were classified as either clinical cure (4, 50%) or indeterminate (4, 50%). There were no clinical failures. The 4 patients with indeterminate clinical response were those patients who were discontinued from study treatment to allow for hospital discharge. These patients were improving clinically to the extent that hospital discharge was possible; however, the protocol did not have a defined clinical response category for improvement. Based on the definitions for clinical outcome, these patients did not meet the definition for cure or failure. The clinical response of indeterminate (extenuating circumstances precluding classification as a cure or failure) was the most appropriate clinical outcome. Per-patient microbiological response at EOT and TOC (Table 6) was categorized as favorable (eradication or presumed eradication), unfavorable (persistence or presumed persistence), or indeterminate. In the Micro-ITT Analysis Set, 5 (50%) patients had favorable response at TOC. Three (3) patients had a response of indeterminate. Each of these 3 patients was discontinued from study treatment to allow for hospital discharge, resulting in a clinical outcome of indeterminate (despite improving clinically). In the absence of follow-up culture data for these patients, the per-pathogen response was indeterminate by definition. Because the protocol did not require that post-baseline cultures be collected, it is not unexpected that patients who were improving clinically would have no follow-up culture data available. Two patients had an unfavorable response in the Micro-ITT Analysis Set. One of the patients with an unfavorable response had an E. coli at baseline in urine that was not susceptible to ceftaroline (MIC >32 mg/L), but no follow up urine culture was available for this patient at TOC. The other patient had an E. coli (urine, MIC = 0.12 mg/L, extended-spectrum -lactamase [ESBL]-negative) that was persistent at TOC. Both of the patients with unfavorable microbiological response were clinical cures at the EOT and TOC assessments. Table Timepoint EOT TOC Percentages Cohort Microbiological Presumed CI n a. Per-pathogen microbiological response at EOT and TOC was categorized as favorable (eradication or presumed eradication), unfavorable (persistence or presumed persistence), or indeterminate. The per-pathogen microbiological response in the Micro-ITT population at TOC is presented in Table 7. In the Micro-ITT population at TOC, all baseline pathogens had a favorable or indeterminate response at TOC, with the exception of 2 E. coli (as described above in the per-patient microbiological response). had a favorable or indeterminate response at TOC, with the exception of 1 E. coli (as noted above). Of note, the second patient with unfavorable microbiological response mentioned in the Micro-ITT Analysis Set was not included in the MITT Analysis Set because this patient had a baseline E. coli which was resistant to ceftaroline (MIC >32 mg/L). Table Baseline Enterobacter Enterococcus Escherichia Klebsiella Staphylococcus Staphylococcus Staphylococcus Streptococcus Analysis Set) Baseline Streptococcus Source: Favorable by Favorable Presumed Percentages Cohort ITT n Plasma Concentration of Ceftaroline Fosamil: All patients (N=11) contributed at least 1 PK sample for a total of 19 plasma samples; 8 patients contributed 2 samples and 3 patients contributed 1 sample each. No CSF samples were collected from any patients in the study. Ceftaroline fosamil was measurable (>lower limit of quantification [LLOQ]) in only 3 plasma samples (Table 8) while ceftaroline (Table 9) and ceftaroline M-1 (inactive metabolite) (Table 10) were measurable in all 19 plasma samples. Plasma concentrations of ceftaroline fosamil, ceftaroline, and ceftaroline M-1 are listed by cohort. Table Cohort 1 2 3 a b Cohort # Cohort Sex/Agea 1 2 3 [a] [b] Concentrations Cohort # Subjects treated with 4 mg/kg ceftaroline. Other subjects treated with 6 mg/kg ceftaroline. set) Cohort 1 2 3 [a] [b] Cohort # Subjects treated with 4 mg/kg ceftaroline. Other subjects treated with 6 mg/kg ceftaroline. Five (5, 45.5%) patients in the Safety Analysis Set experienced treatment-emergent adverse events (TEAEs) (Table 11). One (1) TEAE was deemed by the Investigator as causally related to study treatment. There was 1 patient who experienced an SAE, which was severe in intensity and considered not related to study treatment. Table AE Any Any Any Any Any Any Includes Percentages Cohort AE a. b. One SAE, salmonellosis, was reported for 1 (9.1%) patient in Cohort 3. The SAE started on Day 29 (21 days after last dose of ceftaroline), was severe, resolved and was considered unrelated to study treatment. The single AE deemed related to study drug, diarrhoea, is a recognized side-effect of ceftaroline treatment and is listed in the prescribing information as occurring in 3% of patients treated with ceftaroline fosamil. This AE does not raise any additional safety concerns related to ceftaroline treatment. CONCLUSIONS: The efficacy results may be summarized as follows:  All patients had a clinical outcome of either cure or indeterminate at EOT and TOC. The 4 patients with indeterminate outcomes had improved clinically and were discharged from the hospital for standard of care treatment.  There were no clinical failures at EOT and TOC.  All patients in the MITT Analysis Set had a favorable or indeterminate microbiological response at EOT and TOC with the exception of 1 patient with persistent E. coli in urine at TOC (MIC = 0.12 mg/L, ESBL negative, clinical cure).  Within the MITT Analysis Set, per-pathogen microbiological response was favorable for all baseline pathogens with the exception of 1 E. coli at TOC (as mentioned above). MITT and Micro-ITT Analysis Sets. There was an additional unfavorable microbiological response in the Micro-ITT Analysis Set for an E. coli with a ceftaroline MIC >32 mg/L at baseline. The safety results may be summarized as follows:  The majority of the AEs reported were mild, non-serious, and resolved with or without treatment.  There were no AEs that lead to discontinuation of study treatment or had a fatal outcome.  No deaths occurred during the study.  There were few laboratory safety analytes that were abnormal; a single laboratory abnormality was PCS.  The AEs and other safety parameters such as laboratory results and vital signs were in line with that expected for the patient population and the expected safety profile of ceftaroline.  No new safety concerns were identified for ceftaroline. Overall Conclusions:  Overall, the AEs reported in this study were consistent with the known safety profile for ceftaroline and were in line with the population under study.  No new safety concerns were identified.  All patients had a clinical outcome of either cure or indeterminate at EOT and TOC assessments.  This study supports the use of ceftaroline as a treatment option for neonatal late-onset sepsis. 